Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06344312 Active, not recruiting - Clinical trials for Stroke, Acute Ischemic

Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism

NCT ID: NCT06315153 Active, not recruiting - Ischemic Stroke Clinical Trials

Comprehensive Assessment of Atherosclerotic Ischemic Stroke Risk and Development of a Prediction Model

CAIS-pre
Start date: January 3, 2022
Phase:
Study type: Observational [Patient Registry]

This observational study was designed for the assessment of plaque vulnerability in patients with carotid atherosclerotic stenosis and the development of predictive models for the occurrence and recurrence of atherosclerotic ischemic stroke. The objectives of the study were as follows: first, to integrate the degree of carotid stenosis and plaque characteristics assessed by vascular ultrasound for a comprehensive assessment of plaque vulnerability; second, to develop an assessment tool for the risk of future ischemic stroke in patients with asymptomatic carotid stenosis by combining vascular risk factors, serologic markers, carotid ultrasound characteristics, and contrast-enhanced ultrasonographic parameters; and third, to incorporate vascular ultrasound parameters into existing predictive models of ischemic stroke recurrence risk to develop a risk assessment tool for atherosclerotic ischemic stroke. The main questions it aims to answer are: - How to screen high-risk patients and those eligible for revascularization from asymptomatic carotid stenosis patients for primary prevention of stroke. - How to improve the prediction accuracy of atherosclerotic ischemic stroke based on existing prediction models for secondary prevention of stroke.

NCT ID: NCT06183567 Active, not recruiting - Anesthesia Clinical Trials

The Effect of Sedoanalgesia and General Anaesthesia on Early Neurological Recovery in Acute Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

The hypothesis of this study is that sedoanalgesia will provide better early neurological recovery than general anaesthesia in acute ischaemic stroke patients undergoing endovascular thrombectomy and to investigate the haemodynamic data of both anaesthetic methods.

NCT ID: NCT06172387 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

Intra-arterial Albumin in Acute Ischemic Stroke After Endovascular Treatment for

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

Stroke is an acute focal injury of the central nervous system caused by cerebral vessels. One in every four people is affected by stroke at different times in life. Globally, stroke is the second leading cause of death and third leading cause of disability in adults. we hypothesized that in patients with acute large vessel occlusive ischemic stroke treated with mechanical thrombectomy, the infusion of 20% human serum albumin solution into the revascularization area can exert a stronger neuroprotective effect.

NCT ID: NCT06018545 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation

AI-REACT
Start date: June 1, 2023
Phase:
Study type: Observational

This study has been added as a sub study to the Simulation Training for Emergency Department Imaging 2 study (ClinicalTrials.gov ID NCT05427838). The purpose of the study is to assess the impact of an Artificial Intelligence (AI) tool called qER 2.0 EU on the performance of readers, including general radiologists, emergency medicine clinicians, and radiographers, in interpreting non-contrast CT head scans. The study aims to evaluate the changes in accuracy, review time, and diagnostic confidence when using the AI tool. It also seeks to provide evidence on the diagnostic performance of the AI tool and its potential to improve efficiency and patient care in the context of the National Health Service (NHS). The study will use a dataset of 150 CT head scans, including both control cases and abnormal cases with specific abnormalities. The results of this study will inform larger follow-up studies in real-life Emergency Department (ED) settings.

NCT ID: NCT05921084 Active, not recruiting - Stroke Clinical Trials

MIND Diet to Improve Cognitive Function in Mild Stroke Patients

MINDICOMS
Start date: July 23, 2023
Phase: N/A
Study type: Interventional

A 6-month pilot randomized controlled trial designed to test the effect of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet + usual medical care versus usual medical care on the rate of cognitive change and several other secondary outcomes through a randomized controlled trial in 60 mild stroke patients aged 35-70 years without dementia.

NCT ID: NCT05700591 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

PROST-2
Start date: January 29, 2023
Phase: Phase 3
Study type: Interventional

Intravenous thrombolysis is the first-line therapy in patients with acute ischemic stroke within 4·5 hours of symptom onset, and recombinant tissue plasminogen activator (alteplase) is the preferred thrombolytic agent for this purpose. RhPro-UK is a specific plasminogen activator. rhPro-UK only acts on occlusive thrombus and has little effect on hemostatic thrombus. In addition, rhPro-UK does not form covalent complexes with protease inhibitors in plasma, so the concentrations of rhpro-UK and protease inhibitors in the blood do not decrease compared with alteplase. Therefore, rhPro-UK therapies have a potential advantage of less systemic bleeding in treated subjects. Data from several previous studies suggest that rhPro-UK is efficacious when used to treat patients with acute myocardial infarction. On April 2, 2011, rhPro-UK injection was approved by the National Medical Products Administration to treat acute myocardial infarction. Since then, rhPro-UK has been widely used to treat myocardial infarction in China. Since 2016, a phase 2 clinical trial was carried to explore the dosing of rhPro-UK in patients with acute ischemic stroke, followed by another study with a sample size of 680 patients to initially validate the efficacy and safety of the proposed dose of 35mg. The results of these studies suggested that rhPro-UK was effective, and there were no safety concerns. To further prove the efficacy and safety of rhPro-UK in patients with acute ischemic stroke, investigators conducted this phase 3 study (PROST-2).

NCT ID: NCT05700097 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

To assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy.

NCT ID: NCT05281549 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)

Start date: May 2, 2021
Phase: Phase 2
Study type: Interventional

The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1:1 to 0.25mg/kg or 0.40mg/kg intravenous tenecteplase or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.

NCT ID: NCT05188417 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke

RESET
Start date: December 9, 2021
Phase: Phase 2
Study type: Interventional

The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic stroke